Earnings summaries and quarterly performance for ALNYLAM PHARMACEUTICALS.
Executive leadership at ALNYLAM PHARMACEUTICALS.
Yvonne Greenstreet
Detailed
Chief Executive Officer
CEO
JP
Jeffrey Poulton
Detailed
Executive Vice President, Chief Financial Officer
KF
Kevin Fitzgerald
Detailed
Executive Vice President, Chief Scientific Officer
PG
Pushkal Garg
Detailed
Executive Vice President, Chief Research and Development Officer
RH
Robert Hesslein
Detailed
Executive Vice President, Chief Legal Officer and Secretary
TT
Tolga Tanguler
Detailed
Executive Vice President, Chief Commercial Officer
Board of directors at ALNYLAM PHARMACEUTICALS.
AS
Amy Schulman
Detailed
Chair of the Board
CB
Carolyn Bertozzi
Detailed
Director
CR
Colleen Reitan
Detailed
Director
DP
David Pyott
Detailed
Director
DA
Dennis Ausiello
Detailed
Director
ES
Elliott Sigal
Detailed
Director
MH
Margaret Hamburg
Detailed
Director
MB
Michael Bonney
Detailed
Director
OB
Olivier Brandicourt
Detailed
Director
PK
Peter Kellogg
Detailed
Director
Research analysts who have asked questions during ALNYLAM PHARMACEUTICALS earnings calls.
RB
Ritu Baral
TD Cowen
8 questions for ALNY
Also covers: ACAD, ATAI, BOLD +11 more
TA
Tazeen Ahmad
Bank of America
8 questions for ALNY
Also covers: ACAD, APLS, ARGX +23 more
LI
Luca Issi
RBC Capital Markets
7 questions for ALNY
Also covers: ADVM, ALLO, AMGN +13 more
JF
Jessica Fye
JPMorgan Chase & Co.
6 questions for ALNY
Also covers: ALKS, AMRN, ASND +23 more
Gena Wang
Barclays
4 questions for ALNY
Also covers: BCRX, BLUE, BMRN +13 more
MR
Maury Raycroft
Jefferies
4 questions for ALNY
Also covers: ABEO, ARWR, BCRX +14 more
Paul Matteis
Stifel
4 questions for ALNY
Also covers: ABOS, ACAD, ALKS +11 more
Salveen Richter
Goldman Sachs
4 questions for ALNY
Also covers: ACAD, AGIO, ALLO +21 more
EM
Eliana Merle
UBS
3 questions for ALNY
Also covers: APLS, ARVN, ARWR +17 more
EM
Ellie Merle
UBS Group AG
3 questions for ALNY
Also covers: ALT, ARVN, ARWR +12 more
Gary Nachman
Raymond James
3 questions for ALNY
Also covers: ABBV, ACHV, ADMA +9 more
AJ
Adithya Jayaraman
Evercore
2 questions for ALNY
Also covers: MRNA
HW
Huidong Wang
Barclays
2 questions for ALNY
Also covers: BCRX, BEAM, BLUE +15 more
JS
James Sheehan
Goldman Sachs
2 questions for ALNY
JP
Julian Pino
Jefferies
2 questions for ALNY
Also covers: ACAD, ALEC, ALKS +3 more
KB
Konstantinos Biliouris
BMO Capital Markets
2 questions for ALNY
Also covers: BEAM, BMRN, LEGN +3 more
Kostas Biliouris
BMO Capital Markets
2 questions for ALNY
Also covers: BMRN, LEGN, NTLA +2 more
KT
Kostas Theodoslou
Oppenheimer
2 questions for ALNY
MU
Michael Ulz
Morgan Stanley
2 questions for ALNY
Also covers: ARWR, FATE, GUTS +8 more
MU
Mike Ulz
Morgan Stanley
2 questions for ALNY
Also covers: ARWR, IONS, RYTM +1 more
MM
Myles Minter
William Blair & Company
2 questions for ALNY
Also covers: ALEC, ARCT, ARGX +12 more
PC
Paul Chiaramonte
Citadel
2 questions for ALNY
AC
Alexander Canani
Truist
1 question for ALNY
Cory Kasimov
Evercore ISI
1 question for ALNY
Also covers: BBIO, BMRN, BNTX +7 more
DL
David Lebowitz
Citigroup Inc.
1 question for ALNY
Also covers: ARWR, ASND, BPMC +11 more
MF
Mani Foroohar
Leerink Partners
1 question for ALNY
Also covers: ADVM, ARWR, BBIO +9 more
MR
Maurice Raycroft
Jefferies Financial Group
1 question for ALNY
Also covers: ABEO, AFMD, ARWR +14 more
TT
Ted Tenthoff
Piper Sandler & Co.
1 question for ALNY
Also covers: ARVN, CLRB, CUE +3 more
TV
Teresa Vitali
Scotiabank
1 question for ALNY
Also covers: GERN
TV
Theresa Vitelle
Scotiabank
1 question for ALNY
Tommie Reerink
Goldman Sachs
1 question for ALNY
Also covers: ATRA, BMRN, BPMC +2 more
Recent press releases and 8-K filings for ALNY.
Alnylam Pharmaceuticals Discusses AMVUTTRA Growth, 2026 Revenue Guidance, and Pipeline Progress
ALNY
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- AMVUTTRA's revenue growth is driven by category expansion (40% annual growth in treated patients), strong market access (over 90% of patients have first-line access), and a mid-to-high twenties market share in the first-line segment as of Q3.
- Alnylam projects its TTR franchise revenue to reach $4.4 billion-$4.7 billion in 2026, representing 83% growth at the midpoint year-over-year.
- The company's "Alnylam 2030" goals include a 25% total revenue CAGR and 30% operating margins across the period, with 30% of revenues reinvested in R&D to expand the pipeline and diversify beyond TTR.
- Key pipeline updates include nucinersen (next-gen TTR therapy) with polyneuropathy launch expected in 2028 and cardiomyopathy launch in 2030, and proof-of-concept data expected by year-end for REV-14 (diabetes) and plasminogen (bleeding disorders).
- Alnylam maintains a strong competitive position against WAINUA, having captured 70% of new patient starts in polyneuropathy since WAINUA's launch, citing advantages in dosing frequency and safety profile.
7 days ago
Alnylam Pharmaceuticals Discusses Growth Strategy and Pipeline at TD Cowen Conference
ALNY
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Alnylam provided 2026 revenue guidance for its franchise of $4.4 billion to $4.7 billion, representing 83% growth at the midpoint, and projected a 25% total revenue CAGR with 30% operating margins through 2030.
- AMVUTTRA's revenue growth is sustainable, supported by an under-diagnosed/under-treated market growing approximately 40% annually and over 90% first-line patient access without step edits. The company captured approximately 70% of new patient starts in polyneuropathy following a competitor's launch.
- The next-generation TTR therapy (nucleoside) is expected to launch for polyneuropathy in 2028 and cardiomyopathy in 2030, aiming for twice-a-year dosing and 95% knockdown, which could further consolidate and grow the TTR franchise while expanding operating margins to at least mid-40s%.
- Alnylam plans to reinvest 30% of revenues in R&D to expand its pipeline, targeting 10 tissues and two or more new therapies beyond TTR by 2030, with key assets including zilebesiran (Phase 3), GRAB fourteen (Phase 2 data by year-end), and plasminogen (Phase 2 data by year-end).
7 days ago
Alnylam Pharmaceuticals Outlines 2030 Growth Strategy and Pipeline Progress
ALNY
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Alnylam Pharmaceuticals provided 2026 revenue guidance for its TTR franchise of $4.4 billion to $4.7 billion, representing 83% growth at the midpoint, and projects a total revenue Compound Annual Growth Rate (CAGR) of 25% through 2030.
- The company targets 30% operating margins through 2030, with 30% of revenues reinvested in R&D to support pipeline expansion and achieve a goal of 2+ new therapies beyond TTR by 2030.
- AMVUTTRA maintains strong market access with 90%+ of patients having access as a first-line therapy and held a mid to high twenties share in the first-line market as of Q3. The company also captured 70% of new patient starts in polyneuropathy following a competitor's launch.
- Alnylam is progressing its next-generation TTR therapy, nucleoside, with expected launches in 2028 for polyneuropathy and 2030 for cardiomyopathy, aiming to consolidate and grow the TTR franchise.
- Significant pipeline updates include anticipated Phase 2 data by year-end for GRAB fourteen (diabetes) and plasminogen (bleeding disorders), as well as Phase 1 data for its Huntington's disease program.
7 days ago
Alnylam Pharmaceuticals Reports Strong 2025 Financials and Provides Robust 2026 Guidance
ALNY
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Alnylam Pharmaceuticals achieved nearly $3 billion in combined net product revenues in 2025, marking an 81% growth compared to 2024, and reached GAAP profitability for the full year.
- For 2026, the company projects combined net product sales to be between $4.9 billion and $5.3 billion, representing 71% growth at the midpoint compared to 2025, primarily driven by the TTR franchise.
- Key strategic advancements in 2025 included the initiation of 3 Phase 3 studies (zilebesiran and nucresiran), the expansion of the clinical pipeline with 4 new proprietary programs, and the launch of the Syrelis manufacturing platform.
- The AMVUTTRA launch for ATTR cardiomyopathy demonstrated strong early momentum, contributing to Q4 2025 global TTR net revenues of $858 million, a 151% growth year-over-year, with over 90% of payers now providing first-line coverage.
Feb 12, 2026, 1:30 PM
Alnylam Pharmaceuticals Reports Strong Q4 and Full Year 2025 Results, Issues 2026 Guidance
ALNY
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Alnylam Pharmaceuticals reported nearly $3 billion in combined net product revenues for full year 2025, an 81% growth compared to 2024, and achieved GAAP profitability for the full year, with expectations to sustain it going forward.
- In Q4 2025, combined net product revenues reached $995 million, marking 121% growth year-over-year and 17% growth versus the prior quarter.
- The company provided 2026 guidance for combined net product sales between $4.9 billion and $5.3 billion, representing 71% growth at the midpoint compared to 2025. Collaboration and royalty revenue is projected to be $400 million-$500 million, a 38% decrease at the midpoint due to a non-recurring 2025 milestone.
- Alnylam outlined its "Alnylam 2030" goals, aiming for over 25% revenue CAGR through 2030 and a non-GAAP operating margin of approximately 30% across the period.
Feb 12, 2026, 1:30 PM
Alnylam Pharmaceuticals Reports Strong Q4 and Full-Year 2025 Results, Issues Positive 2026 Guidance
ALNY
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Alnylam Pharmaceuticals reported full-year 2025 combined net product revenues of $2,987 million, an 81% year-over-year increase, and achieved GAAP Profitability.
- For Q4 2025, combined net product revenues reached $995 million, demonstrating 121% year-over-year growth, with a non-GAAP operating income of $203 million and a 19% non-GAAP operating margin.
- The company issued 2026 full-year guidance, forecasting total net product revenues between $4,900 million and $5,300 million, representing 64% to 77% growth over 2025.
- Alnylam ended Q4 2025 with $2,908 million in cash, cash equivalents, and marketable securities.
- As part of its Alnylam 2030 strategy, the company aims for a 25%+ total revenue CAGR through YE 2030 and a ~30% non-GAAP operating margin, supported by a pipeline of over 25 active clinical programs.
Feb 12, 2026, 1:30 PM
Alnylam Pharmaceuticals Reports Strong 2025 Results, Achieves Profitability, and Provides Robust 2026 Guidance
ALNY
Earnings
Guidance Update
Product Launch
- Alnylam Pharmaceuticals reported nearly $3 billion in combined net product revenues for full-year 2025, an 81% increase over 2024, primarily driven by the successful launch of AMVUTTRA for ATTR cardiomyopathy, and achieved GAAP profitability for the full year.
- For Q4 2025, combined net product revenues reached $995 million, demonstrating 121% year-over-year growth and 17% sequential growth.
- The company issued strong 2026 guidance, anticipating combined net product sales between $4.9 billion and $5.3 billion, representing 71% growth at the midpoint compared to 2025.
- Alnylam initiated three Phase 3 studies in 2025 and expanded its clinical pipeline to over 25 programs, while also launching the Syrelis manufacturing platform.
- Long-term Alnylam 2030 goals include achieving over 25% revenue CAGR and approximately 30% non-GAAP operating margin through 2030, with aspirations for global TTR leadership and additional blockbuster medicines.
Feb 12, 2026, 1:30 PM
Alnylam Pharmaceuticals Reports Strong Q4 and Full Year 2025 Results, Achieves Profitability, and Issues 2026 Guidance
ALNY
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Alnylam Pharmaceuticals reported global net product revenues of $995 million for Q4 2025 and $2,987 million for Full Year 2025, representing 121% and 81% growth respectively compared to the same periods in 2024.
- The company achieved GAAP and non-GAAP profitability for Full Year 2025, with sustainable growth in operating income expected.
- Alnylam announced 2026 financial guidance, projecting total net product revenues between $4,900 million and $5,300 million and non-GAAP R&D and SG&A expenses between $2,700 million and $2,800 million.
- Cash, cash equivalents, and marketable securities increased to $2.91 billion as of December 31, 2025, up from $2.69 billion as of December 31, 2024, primarily due to improved operating performance.
Feb 12, 2026, 1:05 PM
Alnylam Pharmaceuticals Reports Strong Q4 and Full Year 2025 Financial Results and Provides 2026 Guidance
ALNY
Earnings
Guidance Update
New Projects/Investments
- Alnylam Pharmaceuticals reported global net product revenues of $995 million for Q4 2025, a 121% increase compared to Q4 2024, and $2,987 million for full year 2025, an 81% increase compared to full year 2024.
- The company achieved GAAP net income of $313,747 thousand and non-GAAP net income of $683,644 thousand for Full Year 2025, marking its first year of GAAP and non-GAAP profitability.
- Alnylam provided full-year 2026 guidance for total net product revenues between $4,900 million and $5,300 million, representing 64% to 77% growth over 2025.
- The company announced 2026 pipeline goals including 4 clinical readouts, 3 ongoing pivotal studies, 3 Phase 2 study initiations, and 3+ new IND filings, and plans a $250 million investment to expand its manufacturing facility.
Feb 12, 2026, 1:00 PM
Alnylam Outlines Ambitious 2030 Growth Strategy and Reports Strong 2025 Financials
ALNY
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Alnylam exceeded its P5x25 goals by the end of 2025, reporting nearly $3 billion in combined net product revenues, an 81% year-over-year growth, largely due to the landmark approval and launch of Amvuttra for ATTR cardiomyopathy.
- The company projects 2026 net product revenue guidance of $4.9 billion to $5.3 billion, with the TTR franchise expected to contribute $4.4 billion to $4.7 billion, representing 83% growth at the midpoint.
- Alnylam unveiled its Alnylam 2030 goals, targeting 25% or greater total revenue CAGR through 2030, approximately 30% Non-GAAP operating margin, and global TTR leadership.
- Key to the 2030 strategy is the launch of Nucresiran, a next-generation TTR silencer, in polyneuropathy by 2028 and cardiomyopathy by 2030, alongside expanding the pipeline to over 40 clinical programs across 10 tissue types.
Jan 12, 2026, 5:00 PM
Quarterly earnings call transcripts for ALNYLAM PHARMACEUTICALS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more